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ABSTRACT 
David T.  Hinkle IV 
 
CORRELATING IRINOTECAN AND CAPECITABINE TREATMENT FOR 
COLORECTAL CANCER TO GENE EXPRESSION, POLYMORPHISMS, AND 
CLINICAL OUTCOMES 
 
Colorectal cancer is the third most common type of cancer and the third most common 
cause of cancer-related mortality.  There are three types of treatment available to patients, 
either individually or in combination.  Treatments are radiation, chemotherapy, and 
surgery.  In a Phase II clinical trial at IUSM, a multimodality approach was chosen.  The 
patients with locally advanced rectal cancer received preoperative treatment with 
capecitabine and irinotecan (CPT-11) combination followed by chemoradiation with 
capecitabine and finally surgery to improve response and decrease local recurrence.  
Irinotecan and Capecitabine are both prodrugs activated in vivo to SN-38 and 5-FU, 
respectively. Identification of the molecular markers for 5-FU and Irinotecan efficacy and 
toxicity is important for the development of more efficient and less toxic treatment 
strategies for patients with colorectal cancer.  The goal of this study was to determine the 
expression levels of the genes involved in activation and metabolism of capecitabine and 
irinotecan in pre and post treatment specimens from these patients.  The genes quantitated 
by real-time PCR were carboxylesterase 1 and 2 (CES1 and CES2), thymidylate synthase 
(TS), β-glucoronidase (β-GUS), thymidine phosphorylase (TP), dihydropyrimidine 
dehydrogenase (DPD) and topoisomerase I (Topo I).  The UGT1A1*28 polymorphism in 
v 
 
UDP glucuronosyltransferase 1 is associated with SN-38 toxicity.  Therefore, the 
UGT1A1*28 polymorphism status in patients was determined by PCR-sequencing.  
Correlative analysis of gene expression and UGT1A1*28 mutation with clinical outcome 
in this Phase II study was completed. 
 
Maureen A. Harrington, Ph.D., Chair 
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INTRODUCTION 
I. Colorectal Cancer 
Colorectal cancer is the third most common type of cancer and the third most common 
cause of cancer related mortality.  Although incidence has been steadily decreasing, the 
NIH estimated colorectal cancer to cause 49,960 deaths in 2008 (1).  Colorectal cancer is 
an uncontrolled proliferation of cells in the largest part of the large intestine, the colon or 
rectum.  Most colorectal cancers are adenocarcinomas, meaning they originate from the 
glandular cells that line the intestine (2). 
 
Staging is the categorization of cancer according to the extent that it spreads.  It is used 
for diagnostic, therapeutic, and prognostic purposes.  There are several staging systems, 
but the most common system is the American Joint Committee on Cancer (AJCC) 
system, also called the TNM system.  This system uses Roman Numerals I-IV to describe 
the extent of the primary Tumor (T), the absence or presence of metastasis to nearby 
lymph Nodes (N), and the absence or presence of distant Metastasis (M) (3).  
Tumor 
T1:  Tumor invades submucosa 
T2:  Tumor invades muscularis  
T3:  Tumor invades serosa 
T4:  Tumor invades other organs/structures 
Node  
N0:  No regional lymph node invasion 
N1:  Metastasis in 1-3 regional lymph nodes 
N2:  Metastasis in 4 or more regional nodes 
Metastasis 
M0:  No distant metastasis 
M1:  Distant metastasis present 
Table 1:  TNM System:  (American Cancer Society.  Detailed Guide:  Colon and 
Rectum Cancer, How is Colorectal Cancer Staged).  
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Stage I:  T1 N0 M0; T2 N0 M0.   
Cancer is contained to inner lining. 
Stage II:  T3 N0 M0; T4 N0 M0. 
Cancer has spread to other nearby organs, but not 
reached lymph nodes. 
Stage III:  any T, N1-2, M0.   
Cancer has spread to lymph nodes, but has not 
been carried to distant parts of the body 
Stage IV:  any T, any N, M1. 
Cancer has been carried through the lymph 
system to distant parts of the body.  The most 
likely organs are the lungs and liver 
 Table 2:  Staging of Colon Cancer (American Cancer Society.  Detailed Guide:  Colon 
and Rectum Cancer, How is Colorectal Cancer Staged). 
 
II. Treatment for Colorectal Cancer 
There are three types of treatment available for patients with colorectal cancer.  They are 
Primary Surgical Therapy, Adjuvant Chemotherapy, and Adjuvant Radiation Therapy 
(4).  The route of therapy chosen is selected according to the stage of the disease.   
 
Primary Surgical Therapy 
Surgery is often the main treatment for colorectal cancer.  It is often the best choice, 
when the cancer has not metastasized.  Surgery may be used alone, or it may be 
employed with other options, such as chemotherapy or radiation therapy.  Advanced 
techniques have greatly improved cure rates and reduced the level of damage to normal 
tissue (5).   
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Radiation Therapy 
Radiation therapy is one of the most common forms of treatment for cancer.  It uses high-
energy particles to attack the cancer cells.  It may be used by itself, or in conjunction with 
another form of treatment (6).  Unlike Chemotherapy, radiation is localized to the area of 
the tumor.   
 
Chemotherapy 
Chemotherapy is a common method of cancer treatment.  It employs the use of 
chemical/biological compounds to destroy cancer cells.  These drugs may be used alone, 
or in combination with other drugs.  And unlike surgery and radiation therapy, 
chemotherapy is a primarily systemic treatment (7).  This means the drugs are not 
localized to a specific region.  Rather, they are administered to the patient in such a way 
that would allow them to travel throughout the body, reaching the cancer cells wherever 
they may have spread.   
 
Chemotherapy Options for Colorectal Cancer 
A variety of drugs are available for patients with colorectal cancer.  The most common 
drug is 5-Fluorouracil (5-FU).  5-FU may be administered intravenously or orally, along 
with Leucovorin.  It is frequently given with another drug, such as Camptosar 
(irinotecan) or oxaliplatin, or with targeted therapies, that involve the use of monoclonal 
antibodies for specific proteins.  These monoclonal antibodies may include Bevacizumab 
(Avastin), which targets vascular endothelial growth factor (VEGF), or Cetuximab 
(Erbitux) and Panitumumab (Vectibix), which target epidermal growth factor receptor 
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(EGFR) (8).  Capecitabine, a prodrug of 5-FU, is increasingly used, as it is an oral drug 
and has minimal side effects.  
 
 
III. Clinical Trial 
This study was part of a Phase II clinical trial conducted at the Indiana University School 
of Medicine, Indianapolis.  Patients were selected according to colorectal cancer staging, 
using endoscopic ultrasound (EUS).  Those with T3/T4 or ≥ N1 rectal cancer were 
treated with capecitabine 1000 mg/m
2
 twice daily for days 1-14 and irinotecan 200 
mg/m
2
 IV on the first of every 21 days for 2 cycles.  This was followed by capecitabine 
825 mg/m
2
 twice daily days 1-5 weekly with concurrent radiotherapy 50.4 Gy in 28 1.8-
Gy fractions.  Baseline tumor biopsies were tested for correlative studies of genes 
expression with clinical endpoints 4-6 weeks after completion of preoperative therapy.  
The objectives of this trial were to assess pathological success rate, toxicity, rate of 
recurrence, clinical response to induction chemotherapy, and perform biological 
correlative studies of the enzymes involved in capecitabine and irinotecan metabolism.   
 
Figure 1.  Clinical Trial Schema 
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IV. Capecitabine and Irinotecan 
The first-line treatment of metastatic colorectal cancer is typically Irinotecan, used in 
conjunction with Capecitabine.  As carbamate prodrugs, both require in vivo activation by 
carboxylesterases (9).   
 
Irinotecan:  Structure and Function 
Irinotecan (Figure 2) is a semisynthetic, water-soluble derivative of the natural alkaloid, 
camptothecin, and is a carbamate ester prodrug of SN-38 (7-12).  It works by inhibiting 
DNA Topoisomerase I, which is encoded by the gene TOPO I (9). Topo I is a nuclear 
enzyme involved in DNA replication, transcription, and DNA repair and recombination.  
During DNA replication, topoisomerase works by breaking one DNA strand and 
covalently binding to the 3’-phosphoryl end.  Irinotecan prevents ligation of the nicked 
strand by stabilizing the DNA-topoisomerase I complex.  This eventually leads to a 
double-strand break and results in apoptosis (10). 
 
Figure 2.  Molecular Structure of Irinotecan 
 
Metabolism of Irinotecan  
Irinotecan exists in two forms, an active lactone form and an inactive carboxylate form, 
that exist in a pH-dependent equilibrium (9).  Irinotecan is converted to several different 
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metabolites by various enzymes.  It is converted by carboxylesterases to its active form 
SN-38, and by the cytochrome CYP3A4 to form the compounds NPC and APC.  APC is 
not further metabolized, but NPC is also converted by carboxylesterases to yield SN-38. 
(10).  SN-38 then undergoes glucuronidation by UGT1A/7 to yield the inactive SN-38G.  
Various bacteria produce the enzyme β-glucuronidase (β-GUS), which then converts SN-
38G back to the active metabolite, SN-38 (Figure 3) (9-14). 
 
Figure 3.  Irinotecan (CPT-11) Metabolism 
Irinotecan exists in two forms, an active lactone form and an inactive carboxylate form, 
that exist in a pH-dependent equilibrium.  Irinotecan is converted to several different 
metabolites by various enzymes.  It is converted by esterases to form SN-38, and by 
CYP3A4 to form the compounds NPC and APC.  APC is not further metabolized, but 
NPC is also converted by carboxylases to yield SN-38.  SN-38 then undergoes 
glucuronidation by UGT1A/7 to yield the inactive SN-38G.  Various bacteria produce the 
enzyme β-glucuronidase, which then converts SN-38G back to the active metabolite, SN-
38.   
 
Capecitabine:  Structure and Function 
Capecitabine (Figure 4) is an orally administered prodrug of the pyrimidine analog 5-
fluorouracil (5-FU).  5-FU inhibits the production of the nucleotide thymidine by 
inhibiting the enzyme thymidylate synthase (TS) (9-14).  
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Figure 4.  Molecular Structure of Capecitabine   
 
Metabolism of Capecitabine 
Capecitabine is first converted to 5'-deoxy-5-fluorocytidine (5'-DFCR) by 
carboxylesterases.  5'-DFCR is then converted to 5'-deoxy-5-fluorouridine (5'-DFUR) by 
cytidine deaminase.  Next, thymidine phosphorylase (TP) converts 5'-DFUR to 5-FU.  5-
FU inhibits the production of the nucleotide thymidine by inhibiting the enzyme 
thymidylate synthase (TS).  5-FU, however, is inactivated by the enzyme 
dihydropyrimidine dehydrogenase (DPD) (Figure 5) (15). 
 
Figure 5.  Metabolism of Capecitabine 
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V. Carboxylesterases 
Classification and Function 
Carboxylesterases (CES) are members of the α/β hydrolase fold family and are a group of 
enzymes that function in the metabolism of ester and amide prodrugs (16).  They are 
ubiquitously expressed, but levels are highest in the small intestine, liver, and lungs.  
There are five genes of carboxylesterases reported in humans, named CES1-CES5.  The 
vast majority are members of the CES1 or CES2 families.  CES1 substrates generally 
contain a large acyl and a small alcohol group, while substrates for CES2 contain a small 
acyl and a large alcohol moiety (17). 
 
Relationship to Irinotecan and Capecitabine 
Irinotecan and Capecitabine are carbamate prodrugs, which require in vivo activation.  
Irinotecan activation is accomplished by CES2, and to a lesser extent, CES1.  However, 
Capecitabine is activated by both CES1 and CES2.  Irinotecan is converted to SN-38, 
while Capecitabine is converted to 5'-deoxy-5-fluorocytidine (5'-DFCR).   
 
VI. Significance of UGT1A1 
UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A) encodes a specific 
UDP-glucuronosyltransferase (UGT) in the glucuronidation pathway.  UGT1A1 also 
glucuronidates SN-38, converting it to SN-38G, and renders it inactive.  However, 
glucuronidase activity is significantly decreased by the presence of additional TA repeats 
in the TATA sequence of the promoter region.  Patients with a UGT1A1*28 
polymorphism are more likely to experience severe adverse reactions to Irinotecan, such 
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as severe neutropenia and even potentially fatal diarrhea, due to their lower capacity to 
inactivate SN-38 to its glucuronide (10).  There are several possible UGT1A1 (TA)n 
polymorphisms, the most common being variations of (TA)6 and (TA)7 (18). 
  
VII. Biotechniques Utilized 
There were several biotechniques employed in this study.  DNA and RNA isolation, 
Real-Time PCR, DNA sequencing, and the use of enzyme activity assays were all 
employed.  Nucleic Acid (NA) isolation was performed on tissues obtained during 
biopsy.  Samples were immediately frozen, upon procurement, to prevent RNA 
degradation.  Samples were then placed in a buffer, homogenized, and purified NAs were 
obtained with Qiagen kits.  RNA integrity was determined using the 2100 bioanalyzer 
(Agilent) and the RNA integrity number was determined using pico chip.  This 
technology uses picogram quantities of RNAs to determine the RNA integrity and 
quantity.  To quantify gene expression, RNA samples were reverse-transcribed and 
cDNA was used for real-time PCR.  Real-time PCR differs from traditional PCR in that it 
allows for the detection of amplicon during the initial, exponential phase of amplification, 
whereas traditional PCR measures amplicon produced in the final, plateau phase.  This 
allows for earlier and more dependable quantitation of gene expression.  DNA 
sequencing was performed on an automated instrument, using a chain-termination 
method.  This method utilizes dideoxynucleotide triphosphates (ddNTPs) as DNA chain 
terminators.  Samples are separated into four reactions, each using all four standard 
deoxynucleotides (dATP, dGTP, dCTP and dTTP).  To each reaction is added only one 
of the four dideoxynucleotides (ddATP, ddGTP, ddCTP, or ddTTP) (19).  When these 
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labeled nucleotides are incorporated, elongation ceases.  This produces DNA fragments 
of varying lengths.  DNA fragments are denatured and resolved by size.  The differences 
in length are used to determine the sequence of the DNA (20).   
 
VIII. Hypothesis 
It was our hypothesis that higher CES2 expression in tumor tissue would result in better 
patient response, due to localized activation of irinotecan to SN-38.  Also, higher CES2 
expression in normal tissue may be the cause of severe drug related gastrointestinal 
toxicity.   
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AIMS of Thesis 
1. The Primary aim of this study was to evaluate the expression levels of the genes 
responsible for the metabolism of capecitabine and irinotecan in baseline and post-
treatment normal and tumor paired samples obtained from colorectal cancer patients 
enrolled in the Phase II trial.   
2. The second aim was to conduct correlative analyses of gene expression in normal and 
tumor paired samples, and gene expression and clinical outcome.   
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METHODS 
 
I. Materials 
QiaShreddars, Allprep DNA/RNA kits, RNeasy Plus Mini Kits, and QIAquick PCR 
Purification Kit were purchased from Qiagen (Valencia, CA).  Disposable mortars and 
pestles were purchased from Kontes.  SYBR Green kits and GeneAmp Gold RNA PCR 
kits were obtained from Applied Biosystems (Foster City, CA).  All primers were ordered 
from Integrated DNA Technologies (Coralville, IA). 
 
II. Sequencing of UGT1A1 Region 
DNA extraction 
Normal tissue samples were used for UGT1A1 sequencing.  Tissues were excised, 
immediately placed in liquid nitrogen, and stored at -70°C for further use.  Less than 20 
mg of tissue was placed in 350 µL Buffer RLT (Qiagen) and disrupted with disposable 
mortars and pestles (Kontes).  Lysates were homogenized with Qiashredder spin columns 
(Qiagen) and purified with AllPrep DNA spin columns (Qiagen).  DNA was eluted in 50 
µL Buffer EB (Qiagen).  
  
DNA sequencing 
Approximately 400 ng of DNA from normal biopsy tissue was used as a template for 
amplifying a 255 bp region flanking the promoter region of the UGT1A1 gene.  The 
forward primer was 5’-AAGTGAACTCCCTGCTACCTT-3’and the reverse primer was 
5’-CCACTGGGATCAACAGTATCT -3.  Reactions were performed in volumes of 50 
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µL with 1x buffer, 1.75mM MgCl2, 0.8mM of each dNTP, 0.25 M of each primer, and 
0.05U/L AmpliTaq Gold (Applied Biosystems).  PCR conditions were based on those 
of Monaghan et al. (21).  Reactions began at 95°C for 10 minutes, followed by 40 cycles 
of 95°C for 30 s, 58°C for 40 s, and 72°C for 40s.  PCR products were electrophoresed on 
1 percent agarose gels (Sigma) and bands were excised under UV light.  Excised DNA 
bands were purified with the QIAquick Gel Extraction Kit and sequenced using the 
forward primer.  Chromatograms were used to identify the number of TA repeats in the 
TATA box region of the promoter in comparison to the normal promoter sequence 
TATATATATATATAA (18).  
 
III. Gene Expression in Samples 
RNA extraction and quantitation 
Both normal and tumor samples were collected and processed in a manner similar to the 
one described above.  Tissues were excised, immediately placed in liquid nitrogen, and 
stored at -70°C for further use.  Less than 20 mg of tissue was placed in 350 µL Buffer 
RLT (Qiagen) and disrupted with disposable mortars and pestles (Kontes).  Lysates were 
homogenized with Qiashredder spin columns (Qiagen) and purified with AllPrep 
RNA/DNA spin columns (Qiagen).  Flowthrough was collected, combined with an equal 
volume of 70% ethanol, and purified with RNeasy spin columns (Qiagen).  RNA was 
eluted in 30 µL RNase-free water and quantitated using the ND-1000 (Nanodrop).   
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Reverse transcription and real-time PCR 
Gene expression was evaluated using a two-step RT-PCR.  Reverse transcription was 
performed with the GeneAmp Gold RNA PCR kit (Applied Biosystems) “Protocol for 
Two-Step RNA PCR”.  Reverse Transcriptions were set up in 50 µL reactions containing 
1g of total RNA, 0.75U/µL MultiScribe reverse transcriptase, 0.5U/ µL RNase inhibitor, 
1.25 µM oligodeoxythymidylic acid primer, 250 µM of each dNTP, and 2.5mM MgCl2.  
Reactions were performed on the GeneAmp PCR System 2700 (Applied Biosystems).   
 
RT conditions were 25°C for 10 minutes, 42°C for 60 minutes, 68°C for 10 minutes, 95°C 
for 5 minutes, and 40°C hold.  Success of all reverse transcription reactions was verified 
by amplifying a portion of the β-Actin gene, using the GeneAmp Gold RNA PCR kit 
(Applied Biosystems) and primers for β-Actin.  The forward primer was 5’-
GAAGATCAAGATCATTGCTCCTCC-3’and the reverse primer was 5’-
TTTTCTGCGCAAGTTAGGTTTTGTG -3’.  PCR parameters were 95°C for 10 
minutes; followed by 35 cycles of 95°C for 30 seconds, 65°C for 30 seconds, and 72°C 
for 1 minute; 72°C for 5 minutes, and holding at 40°C.  PCR products were 
electrophoresed on 1% agarose gels (Sigma).   
 
For real-time PCR, cDNA equivalent to 20 ng of RNA was added to each 25 l PCR 
reaction.  RT was performed using the same conditions described above.  This created the 
cDNA that was subsequently used for the quantitative real-time PCR assays.  PCR was 
performed on the Eppendorf Realplex instrument (Eppendorf) and standard curves were 
evaluated using the program’s software.  Standards for each gene were created from 
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recombinant vectors constructed in our laboratory and were diluted to concentrations of 3 
copies/ml, 30 copies/mL, 300 copies/mL, 3000 copies/mL, 3E4 copies/mL, 3E5 
copies/mL, and 3E6 copies/mL.  Standards and samples were tested in triplicate.  The 
concentration of primers and the reaction conditions were established to ascertain 
minimal primer dimer and/or non specific product formation and hence increase the 
specificity of the real-time PCR. 
 
Gene Primers 
Conc. 
primer 
(µM) 
Melting  
time 
at 95°C 
(sec) 
Annealing 
 time 
at 65°C 
(sec) 
Extention 
time 
at 72°C 
(sec) 
CES2  F 5’-CCATGGTGATGAGCTTCCTTTTGT-3’  0.5 30 30 60 
 R  5’-AGGTATTGCTCCTCCTGGTCGAA-3’      
CES1 F 5’- AGAGGAGCTCTTGGAGACGACAT-3’ 0.2 30 30 60 
 R 5’- ACTCCTGCTTGTTAATTCCGACC-3’     
TOPO I  F 5’-CGTTCTACCAGGCAAATTCACTGT-3’  0.3 20 15 40 
 R 5’-TGAAATGGGAGAGAGGGAAGGGA-3’      
β-GUS  F 5’-TCAACAAGCATGAGGATGCGGAC-3’  0.3 30 30 60 
 R 5’-TACGCACCACTTCTTCCATCACC-3’      
TP  F 5’-AATGTCATCCAGAGCCCAGAGCA-3’  0.5 30 30 60 
 R 5-GAACTTAACGTCCACCACCAGAG-3’      
TS F 5’-TTTACCTGAATCACATCGAGCCAC-3’  0.5 30 30 20 
 R 5’-GACTGACAATATCCTTCAAGCTCC-3’      
DPD F 5’-GGTCTTCAGTTTCTCCATAGTGGT-3’  0.5 20 20 45 
 R 5’-GACTCTGTCCATCCCAGTCTTGT-3’      
Table 3.  Forward (F) and Reverse (R) Primers for Real-Time PCR:  Reaction 
parameters were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles PCR with the 
temperature and times listed in the table. 
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IV. Patient Data 
There were 22 patients enrolled in the study.  Ages ranged from 36-67, with the median 
age being 54 years.  Samples were obtained for 21 patients.  Of these patients, high-
quality RNA was obtained from 18 samples.   
 
V. Correlative Analysis 
Correlative analysis was done using graphpad prizm.  Data was analyzed using Wilcoxin 
matched paired t-test for comparing normal and tumor paired samples.  The entire group 
of patients was analyzed as a single group.  In addition, post-treatment surgical samples 
were obtained from some patients and the gene expression levels were compared before 
and after treatment.  Unpaired t-test analysis of samples was also done, based on patient 
response.   
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RESULTS 
I. Analysis of Isolated DNA 
We found that most of the DNA samples had an A260/A280 ratio of around 1.8.  Table 4 
lists DNA data for normal and tumor specimens.  Figure 6 provides an example of a 
typical DNA analysis by spectrophotometer.   
  NORMAL DNA TUMOR DNA 
Sample 
Total Amount 
(μg) A260/A280 
Total Amount 
(μg) A260/A280 
GI53-001 181.10 1.87 641.11 1.84 
GI53-002 164.86 1.89 154.89 1.92 
GI53-003 517.10 1.92 475.20 1.88 
GI53-007 97.07 1.86 518.55 1.78 
LO53-502 396.7 1.82 100.83 1.93 
LO53-501 382.78 1.85 298.31 1.83 
LO53-504 353.14 1.86 217.47 1.90 
LO53-503 470.96 1.84 247.14 1.83 
LO53-500 446.49 1.81 446.49 1.85 
LO53-505 284.5 1.86 285.18 1.84 
LO53-506 67.33 1.83 386.11 1.81 
LO53-511  96.85 1.82 665.55 1.90 
LO53-510  554.90 1.82 1075.73 1.86 
LO53-523  309.62 1.86 263.30 1.86 
LO53-515  615.11 1.90 98.40 1.86 
LO53-525  278.80 1.87 156.76 1.85 
LO53-529  391.62 1.92 391.62 1.92 
LO53-528  622.38 1.92 620.98 2.11 
LO53-531  268.58 1.89 125.28 1.90 
Table 4.  Summary of Isolated DNA Data from Normal and Tumor Samples 
 
18 
 
 
Figure 6.  Example of Typical DNA Spectrophotometric Analysis 
 
 
 
 
 
II. Analysis of Isolated RNA  
We found that most of the RNA samples had an A260/A280 ratio of around 2.0.  Table 6 
lists RNA data for normal and tumor specimens.  Figure 7 provides an example of a 
typical RNA analysis by spectrophotometer, while Figure 8 depicts typical data obtained 
from degraded RNA.   
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  NORMAL RNA TUMOR RNA 
Sample 
Total 
Amount (μg) A260/A280 
Total 
Amount (μg) A260/A280 
GI53-001 73.01 2.02 1133.79 2.00 
GI53-002 174.40 2.08 197.82 2.07 
GI53-003 219.42 2.01 335.01 1.99 
GI53-007 235.42 1.86 627.03 2.02 
LO53-502 484.88 2.18 595.94 2.13 
LO53-501 111.88 2.03 294.25 2.10 
LO53-504 201.45 2.04 563.86 2.16 
LO53-503 256.84 2.06 351.59 1.96 
LO53-500 117.01 2.02 131.05 2.06 
LO53-505 284.51 2.01 267.66 2.04 
LO53-506 178.66 2.06 42.56 2.02 
LO53-511  521.15 2.09 1010.61 2.08 
LO53- 510  674.49 2.09 875.31 2.08 
LO53- 523  362.28 2.07 224.42 2.09 
LO53- 515  173.90 2.06 266.43 2.07 
LO53- 525  156.00 2.09 115.64 2.07 
LO53-529  380.71 2.05 712.5 2.11 
LO53- 528  477.89 2.11 854.25 2.09 
LO53- 531  174.44 2.08 287.07 1.89 
Table 5.  Summary of Isolated RNA Data from Normal and Tumor Samples 
 
 
Figure 7.  Example of Typical RNA Spectrophotometric Analysis 
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Figure 8.  Example of Degraded RNA Spectrophotometric Analysis 
 
III. Real-Time PCR 
Overall gene expression was compared between the 18 paired tumor and normal samples.  
All Real-time PCR reactions employed the use of laboratory-generated standard curves.  
(Figure 9) Data is summarized in tables 6 and 7.  Data for baseline standard curves are 
provided in table 8.   
 
Figure 9.  Real-Time PCR Standard Curve:  The example shown here is for CES2.  
The r
2
 value is 0.998.  The x-axis represents cycle number and the Y-axis represents copy 
number. 
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GENE COPY NUMBER 
Sample 
Name 
CES2 
Normal 
CES1 
Normal 
TP 
Normal 
TS 
normal 
β-GUS 
Normal 
DPD 
Normal 
TOPO I 
Normal 
GI53-
001 15287 144 1319 3207 1763 23.6 1983 
GI53-
002 32059 38.9 1315 2380 1633 4.15 2728 
GI53-
003 27488 226 7606 3255 1500 26.4 1848 
GI53-
007 28636 94.4 2518 795 1848 25.6 1453 
LO53-
502 12599 19.3 382 441 549 8.95 950 
LO53-
501 16871 89.7 386 1238 563 5.47 912 
LO53-
504 21292 56.2 1447 867 1498 11.4 1139 
LO53-
503 7795 11.6 478 689 353 2.59 774 
LO53-
500 10695 61.3 348 400 530 6.09 673 
LO53-
505 11017 43.8 88.6 476 603 13.8 583 
LO53-
506 5729 9.94 86.2 55.3 231 3.39 196 
LO53-
511  26506 11 1028 117 771 14.9 2694 
LO53- 
510  20676 43.2 2323 302 1263 55.5 5158 
LO53- 
523  14702 87.5 254 283 3485 16.4 2443 
LO53- 
515  43934 30.4 698 1654 4346 57.5 4879 
LO53- 
525  34759 185 1227 195 1119 51.6 4002 
LO53-
529  32044 34.7 429 901 939 38.2 2887 
LO53- 
531  21888 28.5 1581 154 793 26.7 2486 
Table 6:  Gene Expression in Baseline Normal Samples 
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GENE COPY NUMBER 
Sample 
Name 
CES2 
Tumor 
CES1 
Tumor 
TP 
Tumor 
TS 
Tumor 
β-GUS 
Tumor 
DPD 
Tumor 
TOPO I 
Tumor 
GI53-
001 3996 29.3 1807 15991 3611 16.3 6029 
GI53-
002 8403 15.3 550 733 525 42.9 634 
GI53-
003 2175 202 1256 3513 506 13.6 1013 
GI53-
007 14872 33 1205 829 930 94.6 1381 
LO53-
502 16531 69.7 2309 860 1615 138 1463 
LO53-
501 1853 142 6659 1676 516 118 1026 
LO53-
504 8151 631 5445 3364 2912 205 4624 
LO53-
503 15804 584 2009 1204 1058 133 3773 
LO53-
500 13778 116 3242 1171 970 133 4938 
LO53-
505 5329 3359 1848 3280 719 42 1416 
LO53-
506 4927 55.1 11838 2775 1498 635 1696 
LO53-
511  14049 204 2857 319 1050 0 7538 
LO53- 
510  17171 345 2651 1657 1099 0 5723 
LO53- 
523  2118 7.89 579 240 318 3.02 1114 
LO53- 
515  8625 93.7 2684 1919 4467 193 5268 
LO53- 
525  39743 352 427 215 2081 30 2019 
LO53-
529  16783 53.7 3156 23448 2068 53.6 11726 
LO53- 
531  26410 19 427 80 4356 51.6 1421 
Table 7:  Gene Expression in Baseline Tumor Samples 
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GENE SLOPE INTERCEPT R2   
CES1 -3.406 36.74 0.997 Baseline 
TP -3.295 35.42 0.999 
TS -3.337 37.69 0.996 
CES2 -3.563 37.56 0.995 
TOPO I -3.626 40.78 0.995 
Table 8. Standard Curve Equations for Real-Time PCR Assays 
 
IV. Clinical Trial Outcome Data 
Of the 18 patients who completed all therapy, 10 had complete response (CR), 0 had 
partial response (PR), 7 had stable disease (SD), and 1 had progressive disease (PD).   
Best Response n % 
CR 10 45.50% 
PR 0 0.00% 
SD 7 31.80% 
PD 1 4.50% 
Table 9.  Summary of Clinical Trial Data  
 
V.  Sequencing of UGT1A1 Region 
Normal tissue samples were used for UGT1A1 sequencing.  Chromatograms 
demonstrating two sequences in this region were deemed heterozygous.  Eight patients 
were wild-type homozygous for (TA)6TAA/(TA)6TAA (6/6).  Nine patients were 
heterozygous for (TA)6TAA/(TA)7TAA (6/7).  Three patients were homozygous for 
(TA)7TAA/(TA)7TAA (7/7).  And one patient was heterozygous for 
(TA)5TAA/(TA)6TAA (5/6).  (See Table 4) 
 
 
 
24 
 
Polymorphism Number of Patients 
6/6 8 
6/7 9 
7/7 3 
5/6 1 
Table 10.  UGT1A1*28 Polymorphism Status in Patients 
 
 
 
Figure 10.  Wild-Type UGT1A1 (TA)6TAA/(TA)6TAA (6/6) Chromatogram 
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Figure 11.  Heterozygous (TA)6TAA/(TA)7TAA (6/7) Chromatogram 
 
 
 
Figure 12.  Homozygous (TA)7TAA/(TA)7TAA (7/7) Chromatogram 
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VI. Gene Expression Analysis 
Expression levels in paired CR Tumor and Normal, SD Normal and Tumor, Tumor CR 
and SD, and Normal CR and SD samples were analyzed, using two-tailed t-tests.  As seen 
in Figure 13a, a paired t-test analysis of paired samples showed that the expression of 
CES2 was significantly higher in normal samples in comparison to tumor samples 
(p=0.0051).  Further analysis of patient groups based on response showed the same trend 
in both the complete response group and patients with stable disease, but the p-values 
were higher.  (Figures 13b and 13c) Unpaired t-test analysis of CES2 expression in tumor 
and normal samples based on patient response is shown in Figures 13d and 13e.  CES2 
expression was found to be higher in normal sample in comparison to tumor samples, but 
there was no difference in expression of CES2 based on patient response.  There was 
significant increase in TP expression in tumor samples, as compared to normal samples.  
Similar analysis was done for all the genes.  Table 7 summarizes the t-test results. 
 
  
p Value 
CR  
Normal 
Vs 
Tumor, 
n=6 
SD 
Normal 
Vs 
Tumor, 
n=9 
Tumor  
CR Vs 
SD 
Normal 
CR Vs 
SD 
Tumor 
Vs 
Normal, 
n=18 
CES1 0.257 0.3503 0.208 0.262 0.143 
CES2 0.0068 0.2444 0.0755 0.2937 0.0049 
TP 0.0528 0.6723 0.0299 0.1906 0.096 
TS 0.0568 0.3408 0.7187 0.1866 0.082 
TOPO I 0.1481 0.2323 0.7488 0.3412 0.0542 
β-GUS 0.9742 0.2571 0.3954 0.8799 0.297 
DPD 0.1811 0.0361 0.2697 0.2241 0.0338 
Table 11.  Summary of p Values in Paired Samples 
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Figure 13.  Comparisons of CES2 Expression 
 
 
 
13a 
13b 13b 
13c 13d 
28 
 
 
TP Expression in All Patients
Tumor Normal
0
2000
4000
6000
8000
10000
12000
p=0.0414
T
P
 C
o
p
y
 N
u
m
b
e
r
 
 
 
 
Figure 14.  Comparisons of TP Expression 
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DISCUSSION 
I.  Gene Expression in Paired Normal and Tumor Samples  
About 60% of intravenously administered irinotecan is excreted via feces, of which 32% 
is in the unchanged form (22).  Therefore, there is a great potential for activation of 
irinotecan in the GI tract by local carboxylesterases and this may be responsible for the 
life threatening slow onset diarrhea in some patients.  Conversely, presence of high levels 
of carboxylesterases in the tumor tissue could result in localized activation in the tumor 
and may be associated with better clinical response.  The two most abundant 
carboxylesterases in humans are CES1 and CES2.  CES2 the key carboxylesterase 
enzyme expressed in the GI tract.  In this study, gene expression was compared for 19 
paired normal and tumor samples.  Contrary to our hypothesis, it was found that CES2 
expression was higher in normal samples than in tumor samples.  We essentially found 
CES2 expression to be higher in normal samples than in tumor samples, regardless of 
clinical response. (Figures 13b and 13d).  Earlier in the clinical trial it was determined 
that the administration of loperamide prior to and during chemotherapy significantly 
reduced the GI toxicity.  Therefore all patients received loperamide.  In a previous study, 
our laboratory determined that loperamide was a very good inhibitor of CES2 (IC50 
=0.38 μM) (23).  Since CES2 activity is inhibited by the presence of loperamide, we were 
unable to evaluate the correlation between CES2 and GI toxicity.  
 
CES1 expression is reported to be low in GI tissues (24) in comparison to CES2.  In 
accordance with this, we find very low expression of CES1 in normal and most of tumor 
tissue samples with one exception (Tables 6 and 7).   
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For TP, we found that expression was higher in tumor samples than normal samples, for 
all patients.  High basal level expression of thymidine phosphorylase gene was associated 
with nonresponse to 5-fluorouracil treatment in colorectal tumors (25).  However, 
capecitabine which is the prodrug of 5-FU requires TP for activation and uses this fact to 
achieve higher 5-FU levels specifically in tumors (27).  Miwa et al. studied clinical 
activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with 
metastatic colorectal cancer (mCRC).  They reported a significantly higher time to 
disease progression and overall survival in patients with higher expression of TP as 
assessed by immunohistochemistry.  In the same study, association of the real-time PCR 
data for TP did not show as strong an association with clinical outcome (27).  Here, we 
found TP expression to be significantly higher in tumor samples than in normal samples.  
This is consistent with several other studies (26-30).   
 
TOPO I is necessary for controlling the replication of DNA and the synthesis of proteins.  
It is inhibited by irinotecan, topotecan and camptothecin.  It has been reported in the 
literature that higher levels of TOPO I expression leads to a better clinical response to 
irinotecan (31).  It also has been reported that expression is higher in tumor tissue than in 
normal tissue.  This coincides with our findings, which demonstrated higher TOPO I 
expression levels in tumor samples than in normal samples, irrespective of the clinical 
outcome (31, 32). 
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TS is responsible for the synthesis of thymidine monophosphate (dTMP), which 
eventually is metabolized into thymidine triphosphate (dTTP) (35).  dTTP is essential for 
DNA synthesis and repair.  TS is the target enzyme of 5-FU, as TS inhibition leads to the 
accumulation of deoxy-uridine-monophosphate (dUMP) and depletion of deoxy-
thymidine-monophosphate (dTMP) (36).  This results in an arrest of DNA synthesis, as 
well as increased toxicity.  Higher TS expression has been reported to be associated with 
poor response to 5-FU-leucovorin treatment.  Consistent with other studies, we found TS 
expression to be higher in tumor samples than in normal samples (35, 36).   
 
The relative contributions of carboxylesterases and beta-glucuronidase in the formation 
of SN-38 in human colorectal tumors were studied in vitro and it was found that both 
enzymes contributed equally to the formation of SN-38. β-GUS is expressed in the GI 
tract and is an enteric bacterial enzyme which converts SN-38G back to the active 
metabolite, SN-38 (37).  Therefore, increased β-GUS activity can result in higher SN-
38G levels in the gut and, hence, the GI toxicities associated with irinotecan.  In our 
study, there was no correlation between normal and tumor samples.   
 
DPD is responsible for the degradation of the cytotoxic 5-FU.  It has been reported in the 
literature that high DPD expression is an indicator of poor clinical response (38).  We 
evaluated normal and tumor samples to determine if there was a difference in their 
expression levels and found there to be greater expression in tumor samples than in 
normal samples.   
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II. Gene Expression in Baseline and Surgical Samples 
We evaluated the genes CES1, CES2, TP, TS, and TOPO I in 10 tumor and 11 normal 
samples.  Topo I expression was downregulated in tumor samples, but upregulated in 
surgical normal samples, when compared to baseline samples.  CES2 and TP were both 
upregulated in surgical normal samples, but not in tumor samples.  This is consistent with 
another study, in which it was reported that TP expression increased for up to four weeks 
post radiation in rectal cancer patients (39).  CES1 was upregulated in both tumor and 
normal surgical samples and expression in surgical samples was significantly 
upregulated, overall.   
 
III. Correlation of Gene Expression and Therapeutic Response 
Seven genes were analyzed for correlation between expression and clinical outcome.  The 
most significant correlations involved CES2 and DPD expression.  When comparing 
tumor samples to normal samples in patients with CR and SD, we discovered higher 
CES2 expression in the normal samples.  We also found CES2 expression in tumor 
samples to be higher for patients with SD than those with CR.  We found CES2 
expression to be higher in normal tissue samples than in paired tumor samples, and also 
CES2 expression in tumor samples to be higher for patients with SD than those with CR.  
DPD expression was found to be higher in tumor samples than in normal samples.  This 
correlation was particularly significant among patients with SD and in overall expression.  
Additionally, there were correlations for TS, TP, and CES1.  All demonstrated higher 
levels of expression in tumor samples than in normal samples.  When evaluating for 
correlations between expression and clinical outcome, we found patients demonstrating 
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CR to have significantly higher levels of TS expression in tumor tissue than in normal 
tissue.  We also found there to be significant correlation between TP expression and 
clinical outcome.  For patients with CR, TP expression was higher in tumor samples than 
in normal samples.  Additionally, TP expression in tumor samples was found to be higher 
for patients exhibiting CR than those with SD.  This is consistent with several other 
studies (26-30). 
 
IV. Hypothesis 
Our hypothesis was that CES2 expression would be higher in paired tumor samples than 
in the corresponding normal samples, that higher CES2 expression in tumor tissue would 
result in better patient response, and that higher CES2 expression in normal tissue would 
result in toxicity, such as diarrhea.  This was not observed.  CES2 expression was higher 
in paired normal samples than in tumor samples.  No conclusion could be drawn 
regarding toxicity, due to pretreatment administration of Loperamide.  Loperamide is a 
strong inhibitor of carboxylesterases and makes irinotecan unavailable for metabolism in 
the gut, preventing toxicity (23). 
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